Saturday 17 October 2026
Export SCNI’s income statement to Excel — free account
Scinai Immunotherapeutics Ltd. Sponsored ADR
SCNI Healthcare Biotechnology
Scinai Immunotherapeutics Ltd. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 99.2% from fiscal 2024. In the quarter to June 2026, EPS grew 100.4% and free cash flow grew 51.1%, each against the same quarter a year earlier.
0.75
0.15
−16.67%
Follow SCNI
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | (1,794.09%) | 0.00% | 0.00% |
+8 more TTM periods Free account |
|
| 0.00% | 63.60% | 0.00% | 0.00% | ||
ROIC |
0.00% | (58.65%) | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 86.57% | 0.00% | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (24.60) | — | 0.00 | |
Free Cash Flow |
(6.62) | (9.32) | — | (9.62) | |
Capital Expenditures |
(0.13) | (0.03) | — | (0.03) | |
| Other line items | |||||
Cash ROIC |
(44.53%) | (61.45%) | 0.00% | (103.66%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 3.52 | 0.00 | 0.00 | |
Inventory Turnover |
— | 0.00 | — | — | |
Average Days of Payables |
0.00 | 112.54 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | 0.00 | — | — | |
Tax Rate |
— | 0.00 | — | — | |
Research and Development Expense of Revenue |
— | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | — | — | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Interest Coverage |
— | 2.62 | — | — | |
Operating CF/Net income |
0.00 | (0.90) | — | 0.00 | |
Depreciation/Fixed assets |
0.16 | 0.21 | 0.00 | 0.28 | |
Capex/Depreciation |
(0.07) | (0.01) | — | (0.01) | |
Revenue per Share |
— | 0.00 | — | — | |
Operating CF per Share |
0.00 | (24.53) | — | 0.00 | |
Capex per Share |
0.00 | (0.07) | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates